NEW TREATMENT OPTIONS FOR EXTENSIVE-STAGE SMALL-CELL LUNG CANCER

Abstract

Immune checkpoint inhibitors have been actively evaluated and are showing promising results in the treatment of small-cell lung cancer (SCLC). Atezolizumab is the first programmed death-ligand 1 (PD-L1) inhibitor approved for use in combination with carboplatin and etoposide for the first-line treatment of patients with extensive-stage SCLC. The approval was based on data from IMpower133 study in which atezolizumab and chemotherapy combinations significantly prolonged overall survival and progression-free survival rates compared with chemotherapy only.